Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner’s National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.…
Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App
India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to…
Medkart Champions Generic Drug Quality Amid Rising Consumer Concerns
With growing scrutiny around the quality and reliability of generic medicines in…
EyePoint Announces Proposed Public Offering of Common Stock
October 14, 2025 16:35 ET | Source: EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass.,…
Apollomics, Inc. Company Operational Continuity Update
October 13, 2025 21:22 ET | Source: Apollomics Inc. FOSTER CITY, Calif.,…
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal…
36-Year-Old Man Given a Second Chance at Life With Advanced Heart Pump
INDORE, India, Oct. 9, 2025 /PRNewswire/ -- At Apollo Rajshree Hospitals, a 36-year-old…
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
NEW DELHI, Oct. 9, 2025 /PRNewswire/ -- MSN Laboratories, a leading global…
Rocket Doctor Signs Contracts with Major U.S. Insurers, Expanding Access to Over 7 Million Patients Across California and New York
October 08, 2025 08:00 ET | Source: Rocket Doctor AI Inc. Rocket…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
